Browse SCN2B

Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF07686 Immunoglobulin V-set domain
Function

Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-2 causes an increase in the plasma membrane surface area and in its folding into microvilli. Interacts with TNR may play a crucial role in clustering and regulation of activity of sodium channels at nodes of Ranvier (By similarity).

> Gene Ontology
 
Biological Process GO:0001508 action potential
GO:0002027 regulation of heart rate
GO:0002028 regulation of sodium ion transport
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0003254 regulation of membrane depolarization
GO:0006814 sodium ion transport
GO:0006936 muscle contraction
GO:0006941 striated muscle contraction
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0009636 response to toxic substance
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0017085 response to insecticide
GO:0022898 regulation of transmembrane transporter activity
GO:0030048 actin filament-based movement
GO:0032409 regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032844 regulation of homeostatic process
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0035637 multicellular organismal signaling
GO:0035725 sodium ion transmembrane transport
GO:0042391 regulation of membrane potential
GO:0044057 regulation of system process
GO:0046684 response to pyrethroid
GO:0051899 membrane depolarization
GO:0060047 heart contraction
GO:0060048 cardiac muscle contraction
GO:0060078 regulation of postsynaptic membrane potential
GO:0060371 regulation of atrial cardiac muscle cell membrane depolarization
GO:0061337 cardiac conduction
GO:0070252 actin-mediated cell contraction
GO:0086001 cardiac muscle cell action potential
GO:0086002 cardiac muscle cell action potential involved in contraction
GO:0086003 cardiac muscle cell contraction
GO:0086010 membrane depolarization during action potential
GO:0086012 membrane depolarization during cardiac muscle cell action potential
GO:0086091 regulation of heart rate by cardiac conduction
GO:1902305 regulation of sodium ion transmembrane transport
GO:1903522 regulation of blood circulation
GO:1904062 regulation of cation transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2000649 regulation of sodium ion transmembrane transporter activity
Molecular Function GO:0005216 ion channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005248 voltage-gated sodium channel activity
GO:0005261 cation channel activity
GO:0005272 sodium channel activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0016247 channel regulator activity
GO:0017080 sodium channel regulator activity
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0086006 voltage-gated sodium channel activity involved in cardiac muscle cell action potential
GO:1905030 voltage-gated ion channel activity involved in regulation of postsynaptic membrane potential
Cellular Component GO:0001518 voltage-gated sodium channel complex
GO:0034702 ion channel complex
GO:0034703 cation channel complex
GO:0034706 sodium channel complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-422475: Axon guidance
R-HSA-5576891: Cardiac conduction
R-HSA-1266738: Developmental Biology
R-HSA-445095: Interaction between L1 and Ankyrins
R-HSA-373760: L1CAM interactions
R-HSA-397014: Muscle contraction
R-HSA-5576892: Phase 0 - rapid depolarisation
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SCN2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SCN2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SCN2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1880.772
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4330.688
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9770.414
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.3280.0636
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7620.52
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.8980.149
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.770.288
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8110.408
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7480.0115
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SCN2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SCN2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SCN2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SCN2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SCN2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SCN2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SCN2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSCN2B
Namesodium channel, voltage gated, type II beta subunit
Aliases sodium channel, voltage-gated, type II, beta polypeptide; sodium channel, voltage-gated, type II, beta; sodi ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SCN2B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SCN2B.
ID Name Drug Type Targets #Targets
DB00313Valproic AcidSmall MoleculeABAT, ACADSB, ALDH5A1, HDAC2, HDAC9, OGDH, PPARA, PPARD, PPARG, SC ......23
DB00909ZonisamideSmall MoleculeCA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, ......31
DB05541BrivaracetamSmall MoleculeSCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, S ......15